Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti

Author(s)/Faculty: William J. Sandborn, MD; Jessica R. Allegretti, MD, MPH
Release Date: 3/24/2021Expiration Date: 3/23/2022
Credit Type: CMENumber of Credits: 0.25
Content Type: PodcastProvider:
In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe Crohn’s disease.